Fibrocell Science, Inc.’s LAVIV™ Recognized in the Prestigious Wall Street Journal Technology Innovation Awards
October 16 2012 - 11:35AM
Business Wire
Fibrocell Science, Inc. announced that LAVIV™ (azficel-T)
was recognized in this year’s Wall Street Journal Technology
Innovation Awards. LAVIV, the first and only personalized cell
treatment approved by the FDA to improve the appearance of
nasolabial folds or “smile line” wrinkles,
was named a runner-up in the Medicine and
Biotech category. The Awards recognize companies and products that
have the potential to widely impact their industries and make a
difference in people’s lives.
“We are extremely pleased that The Wall Street Journal
recognized LAVIV as part of its Technology Innovation Awards,” said
David Pernock, Chairman and CEO of Fibrocell Science, Inc. “This
award highlights the innovative technology behind LAVIV, which
isolates, purifies and multiplies a patient’s own
collagen-producing fibroblast cells. We look forward to advancing
our fibroblast platform with new indications for unmet medical
needs beyond aesthetics.”
The Wall Street Journal received 536 applications from more than
two dozen countries. A team of Journal editors and reporters
reviewed the entries and forwarded 172 to an independent panel of
judges from venture-capital firms, universities and companies. From
that pool, the judges chose a total of 37 winners and runners-up in
18 categories.
About The Wall Street Journal Technology Innovation
Awards
In its 12th year, The Wall Street Journal Technology Innovation
Awards recognize technological advances that break with
conventional processes in specific fields, offer more than marginal
improvements compared to existing technology and those that will
have a wide impact on the industry or field.
About Fibrocell Science, Inc.
Fibrocell Science, Inc. (FCSC) is an autologous cellular
therapeutic company focused on the development of innovative
products for aesthetic, medical and scientific applications.
Fibrocell Science, Inc. is committed to advancing the scientific,
medical and commercial potential of autologous skin and tissue, as
well as its innovative cellular processing technology and
manufacturing excellence. For additional information, please visit
www.fibrocellscience.com.
About LAVIV™ (azficel-T)
LAVIV was approved by the FDA on June 21, 2011 for the
improvement of the appearance of moderate-to-severe nasolabial fold
wrinkles in adults and is the first and only personalized cell
treatment approved by the FDA for aesthetic use. The safety and
efficacy of LAVIV for areas other than nasolabial folds have not
been established; nor has the efficacy of LAVIV beyond six months
been established.
LAVIV is now available in major metropolitan areas throughout
the U.S., exclusively through board-certified dermatologists and
plastic surgeons who have been trained by Fibrocell Science, Inc.
on the treatment process. A list of trained and certified
physicians is available at www.mylaviv.com and will be continually
updated as new physicians are trained and begin offering LAVIV in
their practice.
Important Safety Information About LAVIV™ (azficel-T)
LAVIV is made especially for you from your own skin cells. Using
someone else’s cells can cause a serious reaction. Do not let
anyone else use your LAVIV. Prior to injection, confirm with your
physician that your information on the LAVIV vial is correct. Your
healthcare provider will help you to decide whether you are a
candidate for LAVIV and may help you avoid some of the adverse
reactions from LAVIV. Before getting LAVIV, tell your healthcare
provider if you have any medical problems including allergic
reactions to any drugs or food, bleeding disorders or take
blood-thinning medicines like aspirin, ibuprofen, or COUMADIN®
(warfarin sodium), keloids or excessive scarring, skin cancer or
any malignancy, genetic disorders affecting your skin, immune
problems or take medicines that affect your immune system, or any
other illness or medical problem. Tell your healthcare provider if
you are allergic to the antibiotics amphotericin or gentamicin,
bovine materials (products made from cattle), or dimethyl sulfoxide
(DMSO). Do not use LAVIV if you have a skin infection on your face
because LAVIV treatment can make the infection worse.
The most common side effects of LAVIV are at the injection-site,
including redness, bruising, swelling, pain, bleeding, lumps,
irritation, and itchiness. In clinical trials with LAVIV, most
injection-site adverse reactions resolved within one week and most
required no treatment. There are additional adverse reactions that
occurred in less than 1% of patients following LAVIV treatment in
clinical trials. Talk to your healthcare provider about these
adverse reactions. For more information about LAVIV, please see
accompanying full Prescribing Information or visit
www.mylaviv.com.